Clinical Trials Browser

evolocumab × Gastrointestinal × 90 days × Clear all

NCT04862260 2026-03-19

Cholesterol Disruption in Combination With the Standard of Care in Patients With Advanced Pancreatic Adenocarcinoma

Phase EARLY_PHASE1 Active not recruiting

Gastrointestinal

Hyperlipoproteinemia Type II, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms